Euro-BioImaging recently distributed a newsletter on how Euro-BioImaging Nodes are contributing to COVID-19 research and adapting to a new normal.
In the battle against the SARS-CoV-2 virus, imaging technologies play a crucial role. From fundamental research at the molecular and cellular level to medical applications and diagnostics, imaging clearly supports the global response to the pandemic. Euro-BioImaging Nodes are updating their working procedures to continue to provide access to key imaging technologies.
A dedicated EIBIR session will take place during the ECR 2020 Highlight Week on Artificial Intelligence from July 20-23, 2020.
Seize this opportunity to ask the experts about artificial intelligence in medical imaging and learn how to succeed in the European funding landscape.
AI and the future of imaging: European funding prospects
Tuesday, July 21, 2020 10:45 CEST
Introduction by the moderator
G. Langs, Vienna/AT
The importance of artificial intelligence in imaging research
W. Niessen, Rotterdam/NL
Deep learning in imaging and cancer care
G. Langs, Vienna/AT
Applying artificial intelligence for biomarker discovery
A. Alberich-Bayarri, Valencia/ES
European funding and support services for AI and imaging research
P. Zolda, Vienna/AT
Access to all Highlight Weeks is included in every ECR 2020 registration and all weeks will also be available on-demand afterwards. Separate packages are available for non-attendees. Find out how to participate here.
In 2019, European Society of Radiology (ESR) in cooperation with the European Institute for Biomedical Imaging Research (EIBIR) launched a new program is to stimulate and provide funding for innovative projects and pilot studies that will subsequently lead to larger studies and further funding applications: the ESR Research Seed Grant.
Artificial Intelligence and Cardiac Imaging were identified as the funding priorities for 2020. After an extensive review by a panel of 25 international experts, eight proposals were selected for funding:
AI-driven MR-based imaging of tumor hypoxia
Ieva Kurilova, Netherlands Cancer Institute
CT-based radiomics analysis in patients with intraductal papillary mucinous neoplasm (IPMN) of the pancreas
David Tobaly, Hôpital Beaujon Clichy
Integration of a Retina U-Net algorithm for the automated detection of primary lung cancer in clinical workflows
Thomas Weikert, University Hospital Basel
MRI-assessed myocardial deformation of the systemic right ventricle in patients with transposition of the great arteries
Maja Hrabak Paar, University Hospital Center Zagreb
Optimization and validation of highly accelerated compressed sensing whole-heart 4D-Flow imaging
Clemens Reiter, Medical University of Graz
Reliability of cardiothoracic ratio as an estimate of cardiac enlargement compared to gold standard MRI parameters
Monika Arzanauskait, Liverpool Heart and Chest Hospital
RISK – Risk Maps using T2 mapping and Diffusion MR Sequences of the Prostate
Liliana Caldiera, University Hospital Cologne
Spatio-temporal cardiac motion patterns in the non-invasive diagnosis of myocarditis
Fabian Laqua, University Medicine Greifswald
We congratulate the awardees and are looking forward to hearing about the progress in their fascinating research projects during ECR 2021.
Find out more about what the researchers aim to achieve in their projects here.
Euro-BioImaging is inviting applications for the the Directorate positions of the newly formed Euro-BioImaging ERIC
Euro-BioImaging is seeking to recruit excellent candidates for its Directorate positions.
Euro-BioImaging is the European landmark research infrastructure for biological and biomedical imaging technologies as recognised by the European Strategy Forum on Research Infrastructures (ESFRI). Through Euro-BioImaging, life scientists can access cutting-edge imaging instruments, expertise, training opportunities and image data services that they might not find at their home institutions or among their collaboration partners. Euro-BioImaging is structured as a distributed hub, which consists of Finland as the statutory seat, Italy as the medical imaging coordinator (Med-Hub) and EMBL as the biological imaging coordinator and host of the data services (Bio-Hub).
The Directorate of Euro-BioImaging is composed of the Director General, the Section Director of the Med-Hub and the Section Director of the Bio-Hub. The role of the Directorate is to both provide advice to, and implement the decisions of, the Euro- BioImaging Board. In addition, the Directorate will be responsible for: the day-to-day management of the Organisation, promoting the research infrastructure nationally and internationally, ensuring the coordinated provision of access, services and training to state- of-the-art imaging technologies for all life scientists in Europe and beyond and finally, to foster liaison and cooperation across the broad bioimaging communities.
This is an exciting leadership opportunity to form the foundation senior management team as fulltime employees to further build, develop and coordinate the recently established Euro-BioImaging ERIC. The mission of this new research infrastructure is to provide the European research community, collaborative partners and industry with world class imaging services that bridge biological and biomedical imaging and enable innovative and world- class research. Whatever the scale of imaging, Euro-BioImaging provides the tools and support to explore and answer research questions.
Expressions of interest are therefore invited for the following roles:
– Director General (Statutory seat, Turku, Finland)
– Section Director (Med-Hub, CNR, Turin, Italy)
– Section Director (Bio-Hub and Data Services, EMBL, Heidelberg, Germany)
More information and details on the application procedure is available here.
The Innovative Medicines Initiative (IMI) has launched the last calls for proposals under the IMI2 programme, with topics on tackling cancer through artificial intelligence, antimicrobial resistance, neurodegenerative diseases, rare disease diagnosis, the return of clinical trial data to participants, and patient adherence.
IMI will contribute a total of EUR 59 million to the projects funded under the calls; these funds come from Horizon 2020 and will support the participation in the projects of organisations such as universities, small and medium-sized enterprises, and patient groups. EFPIA companies and IMI Associated Partners will contribute EUR 47 million.
Topic 4 of Call 23, on using artificial intelligence to select the best cancer treatment, is of particular interest to the biomedical imaging community. Advances in research mean that for many cancers, there are more treatment options than ever. Physicians face a growing number of potential therapeutic options, each of which needs to be understood and adopted effectively to ensure each patient receives the right treatment. The goal of this topic is to develop a treatment decision support tool with AI technologies to support decision making and research for cancer. The topic focuses on breast, lung and prostate cancer as there are large numbers of patients, a high unmet medical need, and a rapidly evolving treatment environment. However, it should be possible to apply the project outputs to other cancers afterwards.
Today, the European Commission launched the second Emergency Call on COVID-19 under the Horizon 2020 programme with a total budget of €122 million. Similar to the first Emergency Call in February, the procedure is again expedited. The deadline for the full-length proposals is June 11.
The call includes of five topics:
– Networking of existing EU and international cohorts of relevance to COVID-19 (coordination and support action, €2-3m for 1 project)
– Pan-European cohorts (research and innovation action, €15-20 million)
– Medical technologies, Digital tools and AI analytics to improve surveillance and care at high TRLs (innovation action, €2-5m per project)
– Repurposing of manufacturing for vital medical supplies and equipment (innovation action, €5-6m per project)
– Behavioural, social and economic impacts of the outbreak response (innovation action, €4-10m per project)
To read the full topic description and expected impacts, click on the topic title above.
EIBIR continues to offer its expertise in proposal preparation and project management free-of-charge to everyone applying for COVID-19 research funding provided availability of resources and suitability of project with call topic.
Furthermore, we have compiled an always up-to-date list of open access COVID-19 datasets for teaching, training and/or research (depending on license).
The European Commission is set to launch a second Emergency Call on COVID-19 under the Horizon 2020 programme with a total indicative budget of €120 million.
Similar to the first Emergency Call in February, the procedure will again be expedited. The call is expected to be published on May 14th and the deadline for the full-length proposals expected for June 11th.
Expected topics of the call are:
– Social and economic impacts of the outbreak response and mental health
– Pan-European cohorts united against the pandemic
– Repurposing of manufacturing for vital medical supplies and equipment
– Medical technologies, Digital tools, AI analytics
Unfortunately a draft of the full call text is not yet available. As soon as this becomes available, we will of course share this information.
EIBIR continues to offer its expertise in proposal preparation and project management free-of-charge to everyone applying for COVID-19 research funding – this offer extends to basic and applied research, as well as clinical studies. Furthermore, we have compiled an always up-to-date list of open access COVID-19 datasets for teaching, training and/or research (depending on license).
EIBIR launched an always up-to-date overview of COVID-19 imaging repositories and datasets. You can access the overview here.
Imaging databases and registries are essential for diagnosis in radiology, as well as for the development of artificial intelligence tools for machine-based diagnosis. We have compiled a list of open access COVID-19 repositories, which can be used for teaching, training and/or research. This preliminary overview will be updated continually with new databases and registries as they become available.
Furthermore, EIBIR continues to offer its expertise in proposal preparation and project management free-of-charge to everyone applying for COVID-19 research funding – this offer extends to basic and applied research, as well as clinical studies.
We’re extending our support services to research proposals on COVID-19.
EIBIR is offering its excellent track-record and longstanding experience in proposal preparation and project management free-of-charge to everyone applying for COVID-19 research funding. This offer is extended to basic and applied research, as well as clinical studies. The EIBIR membership policy does not apply for COVID-19-related research proposals.